“There's not enough studies”: Views of black breast and ovarian cancer patients on research participation

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 7; pp. 8767 - 8776
• Main Authors: Riggan, Kirsten A., Rousseau, Abigail, Halyard, Michele, James, Sarah E., Kelly, Marion, Phillips, Daphne, Allyse, Megan A.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2023; John Wiley and Sons Inc; Wiley
• Subjects: African Americans; Black or African American; Breast; Breast cancer; Breast Neoplasms; Cancer research; clinical cancer research; Clinical trials; Clinical Trials as Topic - psychology; community outreach; Female; Humans; Medical research; Ovarian cancer; Ovarian Neoplasms - epidemiology; Ovarian Neoplasms - therapy; Patient Participation - psychology; Patients; Qualitative Research; Research Subjects - psychology; Socioeconomic factors; Syphilis; Trust; women's cancer; United States > US; breast cancer; women's cancer; community outreach; clinical cancer research
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.5622

Background Black breast and ovarian cancer patients are underrepresented in clinical cancer trials disproportionate to the prevalence of these cancers in Black females. Historically, lower enrollment has been attributed to individualized factors, including medical mistrust, but more recently structural factors, including systemic racism, have received additional scrutiny. We interviewed Black women with a personal or family history of breast and ovarian cancer to understand their views and experiences related to research participation. Methods Qualitative interviews were conducted via telephone or video conference and transcribed verbatim. Transcripts were qualitatively analyzed for iterative themes related to the offer and participation in cancer clinical trials and research studies, impact on cancer care, and recommendations to increase enrollment of Black patients. Results Sixty‐one Black women completed an interview. Participants expressed that Black women are underrepresented in cancer research, and that this negatively impacted their own care. Many cited past historical abuses, including the Tuskegee syphilis trial, as a potential factor for lower enrollment but suggested that lower enrollment was better understood in the context of the entirety of their healthcare experiences, including present‐day examples of patient mistreatment or dismissal. Participants suggested that proactive community engagement, transparency, and increased representation of Black research team members were strategies likely to foster trust and bolster research participation. Conclusion(s) Medical mistrust is only a partial factor in the lower participation of Black patients in cancer research. Researchers should implement the strategies identified by our participants to promote diverse enrollment and ensure that Black patients are included in future therapeutic advances.